Trials / Unknown
UnknownNCT03631459
A Multicenter Real World Study of Kanglaite for Cancer Cachexia
Safety and Effectiveness of Kanglaite Injection/Capsules for Treatment of Cancer Cachexia: A Prospective, Multicenter Real World Study of a Large Cohort of Chinese Patients
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 100,000 (estimated)
- Sponsor
- Zhejiang Kanglaite Pharmaceutical Co.Ltd · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
A prospective, multi-center real-world study of the effectiveness and safety of Kanglaita Injection/Capsule in Chinese patients with cancer cachexia
Detailed description
This is a large national-based prospective, multi-center real-world observational study. Cancer cachexia patients scheduled for sequential treatment with Kanglaite injection and capsule between August 2018 and March 2020 at 640 participating hospitals will be recruited to evaluate the effectiveness and safety of Kanglaite.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Kanglaite Injection/Capsules | Kanglaite injection 200 mL, iv. gtt qd×7d or more, followed by Kanglaite capsule 0.45g×6 tablets qid po×14d as one cycle for at least 4 cycles |
Timeline
- Start date
- 2018-08-20
- Primary completion
- 2020-03-20
- Completion
- 2020-07-20
- First posted
- 2018-08-15
- Last updated
- 2018-08-21
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03631459. Inclusion in this directory is not an endorsement.